vs
Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and LANDSTAR SYSTEM INC (LSTR). Click either name above to swap in a different company.
LANDSTAR SYSTEM INC is the larger business by last-quarter revenue ($1.2B vs $722.5M, roughly 1.6× Amneal Pharmaceuticals, Inc.). Amneal Pharmaceuticals, Inc. runs the higher net margin — 10.8% vs 3.4%, a 7.4% gap on every dollar of revenue. On growth, Amneal Pharmaceuticals, Inc. posted the faster year-over-year revenue change (3.9% vs 1.6%). Over the past eight quarters, Amneal Pharmaceuticals, Inc.'s revenue compounded faster (1.5% CAGR vs -2.2%).
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
Landstar System, Inc. is an American transportation services company specializing in logistics and, more specifically, third-party logistics. Landstar utilizes an extensive network of over 8,800 independent owner-operators, referred to internally as business capacity owners (BCOs), over 1,000 independent freight agents, and over 70,000 vetted carriers. Landstar provides services principally throughout the United States and to a lesser extent in Canada and between the U.S. and Canada, Mexico, ...
AMRX vs LSTR — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $722.5M | $1.2B |
| Net Profit | $78.0M | $39.4M |
| Gross Margin | 44.3% | 9.6% |
| Operating Margin | — | 4.5% |
| Net Margin | 10.8% | 3.4% |
| Revenue YoY | 3.9% | 1.6% |
| Net Profit YoY | 217.0% | 32.3% |
| EPS (diluted) | $0.19 | $1.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $722.5M | $1.2B | ||
| Q4 25 | $814.3M | $1.2B | ||
| Q3 25 | $784.5M | $1.2B | ||
| Q2 25 | $724.5M | $1.2B | ||
| Q1 25 | $695.4M | $1.2B | ||
| Q4 24 | $730.5M | $1.2B | ||
| Q3 24 | $702.5M | $1.2B | ||
| Q2 24 | $701.8M | $1.2B |
| Q1 26 | $78.0M | $39.4M | ||
| Q4 25 | $35.1M | $23.9M | ||
| Q3 25 | $2.4M | $19.4M | ||
| Q2 25 | $22.4M | $41.9M | ||
| Q1 25 | $12.2M | $29.8M | ||
| Q4 24 | $-31.1M | $46.2M | ||
| Q3 24 | $-156.0K | $50.0M | ||
| Q2 24 | $6.0M | $52.6M |
| Q1 26 | 44.3% | 9.6% | ||
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 24 | 35.6% | — |
| Q1 26 | — | 4.5% | ||
| Q4 25 | 13.8% | 2.5% | ||
| Q3 25 | 9.0% | 2.2% | ||
| Q2 25 | 15.4% | 4.6% | ||
| Q1 25 | 14.4% | 3.4% | ||
| Q4 24 | 10.4% | 4.8% | ||
| Q3 24 | 12.6% | 5.2% | ||
| Q2 24 | 13.6% | 5.6% |
| Q1 26 | 10.8% | 3.4% | ||
| Q4 25 | 4.3% | 2.0% | ||
| Q3 25 | 0.3% | 1.6% | ||
| Q2 25 | 3.1% | 3.5% | ||
| Q1 25 | 1.8% | 2.6% | ||
| Q4 24 | -4.3% | 3.8% | ||
| Q3 24 | -0.0% | 4.1% | ||
| Q2 24 | 0.9% | 4.3% |
| Q1 26 | $0.19 | $1.16 | ||
| Q4 25 | $0.10 | $0.70 | ||
| Q3 25 | $0.01 | $0.56 | ||
| Q2 25 | $0.07 | $1.20 | ||
| Q1 25 | $0.04 | $0.85 | ||
| Q4 24 | $-0.10 | $1.30 | ||
| Q3 24 | $0.00 | $1.41 | ||
| Q2 24 | $0.02 | $1.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $411.0M |
| Total DebtLower is stronger | — | $26.1M |
| Stockholders' EquityBook value | — | $799.0M |
| Total Assets | — | $1.6B |
| Debt / EquityLower = less leverage | — | 0.03× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $411.0M | ||
| Q4 25 | $282.0M | $452.2M | ||
| Q3 25 | $201.2M | $434.4M | ||
| Q2 25 | $71.5M | $426.2M | ||
| Q1 25 | $59.2M | $473.4M | ||
| Q4 24 | $110.6M | $566.6M | ||
| Q3 24 | $74.0M | $531.3M | ||
| Q2 24 | $43.8M | $504.0M |
| Q1 26 | — | $26.1M | ||
| Q4 25 | $2.6B | $0 | ||
| Q3 25 | $2.6B | $0 | ||
| Q2 25 | $2.2B | $0 | ||
| Q1 25 | $2.2B | $0 | ||
| Q4 24 | $2.4B | $0 | ||
| Q3 24 | $2.4B | $0 | ||
| Q2 24 | $2.4B | $0 |
| Q1 26 | — | $799.0M | ||
| Q4 25 | $-70.8M | $795.7M | ||
| Q3 25 | $-109.5M | $888.7M | ||
| Q2 25 | $-112.1M | $921.8M | ||
| Q1 25 | $-131.7M | $930.8M | ||
| Q4 24 | $-109.3M | $972.4M | ||
| Q3 24 | $-93.4M | $1.0B | ||
| Q2 24 | $-57.5M | $1.0B |
| Q1 26 | — | $1.6B | ||
| Q4 25 | $3.7B | $1.6B | ||
| Q3 25 | $3.6B | $1.7B | ||
| Q2 25 | $3.4B | $1.7B | ||
| Q1 25 | $3.4B | $1.7B | ||
| Q4 24 | $3.5B | $1.8B | ||
| Q3 24 | $3.5B | $1.8B | ||
| Q2 24 | $3.5B | $1.8B |
| Q1 26 | — | 0.03× | ||
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
LSTR
Segment breakdown not available.
